PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 338
- Registration Number
- NCT00483756
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers
Phase 1
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00483353
- Locations
- 🇬🇧
Pfizer Investigational Site, London, England, United Kingdom
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
Phase 3
Terminated
- Conditions
- Obesity
- Interventions
- Behavioral: Non-pharmacological weight loss program (NPP)Behavioral: Low Calorie Diet
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 699
- Registration Number
- NCT00483171
- Locations
- 🇿🇦
Pfizer Investigational Site, Pretoria, South Africa
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3719
- Registration Number
- NCT00483002
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
Not Applicable
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2008-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00483028
- Locations
- 🇺🇸
Pfizer Investigational Site, Albany, New York, United States
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
Phase 2
Completed
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00482664
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Device: Enbrel (etanercept)Device: Etanercept
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT00482170
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT00480636
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Biological: QS-21Biological: ACC-001 + QS-21Biological: ACC-001
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00479557
- Locations
- 🇩🇪
Unversitätsklinikum Freiburg, Freiburg, Baden- Württemberg, Germany
🇫🇷Hôpital LA GRAVE, TOULOUSE Cedex 9, France
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT00479570
- Locations
- 🇸🇪
Pfizer Investigational Site, Danderyd, Sweden
© Copyright 2025. All Rights Reserved by MedPath